ReCode Therapeutics is a pharmaceutical firm specializing in the development of precise drugs for genetic respiratory ailments with substantial unmet clinical requirements. The company's varied pipeline encompasses primary ciliary dyskinesia and nonsense mutations in cystic fibrosis. Their exclusive non-viral lipid nanoparticle technology facilitates the transportation of different payloads and accurate organ targeting of genetic material and protein payloads via systemic and localized delivery approaches. ReCode is capitalizing on its nanoparticle and genetic material technologies across various modalities.